[go: up one dir, main page]

TW238303B - - Google Patents

Info

Publication number
TW238303B
TW238303B TW082109298A TW82109298A TW238303B TW 238303 B TW238303 B TW 238303B TW 082109298 A TW082109298 A TW 082109298A TW 82109298 A TW82109298 A TW 82109298A TW 238303 B TW238303 B TW 238303B
Authority
TW
Taiwan
Prior art keywords
pct
date jun
sec
pub
pyzazolopyrimidines
Prior art date
Application number
TW082109298A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of TW238303B publication Critical patent/TW238303B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW082109298A 1992-12-17 1993-11-06 TW238303B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99222592A 1992-12-17 1992-12-17

Publications (1)

Publication Number Publication Date
TW238303B true TW238303B (zh) 1995-01-11

Family

ID=25538063

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082109298A TW238303B (zh) 1992-12-17 1993-11-06

Country Status (27)

Country Link
US (1) US5712303A (zh)
EP (1) EP0674624B1 (zh)
JP (1) JP2862374B2 (zh)
KR (1) KR0170567B1 (zh)
CN (1) CN1060768C (zh)
AT (1) ATE175961T1 (zh)
AU (1) AU690527B2 (zh)
BR (1) BR9307659A (zh)
CA (1) CA2150483C (zh)
CZ (1) CZ284157B6 (zh)
DE (1) DE69323212T2 (zh)
DK (1) DK0674624T3 (zh)
EG (1) EG20397A (zh)
ES (1) ES2126661T3 (zh)
FI (1) FI113648B (zh)
GR (1) GR3029568T3 (zh)
HU (1) HUT67457A (zh)
IL (1) IL107946A (zh)
MX (2) MX9308042A (zh)
MY (1) MY131382A (zh)
NO (2) NO304831B1 (zh)
NZ (1) NZ257770A (zh)
PL (1) PL175831B1 (zh)
RU (1) RU2142946C1 (zh)
TW (1) TW238303B (zh)
WO (1) WO1994013643A1 (zh)
ZA (1) ZA939404B (zh)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005109A (en) * 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US6103900A (en) * 1992-12-17 2000-08-15 Pfizer Inc Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
HUT74464A (en) 1993-10-12 1996-12-30 Du Pont Merck Pharma 1n-alkyl-n-arylpyrimidinamines and derivatives thereof, and pharmaceutical compositions containing them
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
JPH10509708A (ja) * 1994-11-10 1998-09-22 コア セラピューティクス，インコーポレイティド プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US5817688A (en) * 1995-12-19 1998-10-06 Rhone-Poulenc Inc. Pesticidal 1-arylpyrazole derivatives
US5922885A (en) 1995-12-19 1999-07-13 Rhone-Poulenc Inc. Pesticidal 1-arylpyrazole derivatives
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US5760225A (en) * 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
EP0976745B1 (en) * 1997-03-26 2003-08-13 Taisho Pharmaceutical Co., Ltd 4-tetrahydropyridylpyrimidine derivatives
SE9701398D0 (sv) * 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
US6613777B1 (en) 1998-03-06 2003-09-02 Chen Chen CRF antagonistic pyrazolo[4,3-b]pyridines
JP2002510686A (ja) 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキルで置換された５，６，７，８−テトラヒドロ−９Ｈ−ピリジノ［２，３−ｂ］インドール及び５，６，７，８−テトラヒドロ−９Ｈピリミジノ［４，５−Ｂ］インドール誘導体：ＣＲＦ１特異的配位子
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
US20020156114A1 (en) * 1998-05-05 2002-10-24 Goldstein David Michael Pyrazole derivatives - p38 MAP kinase inhibitors
US6376527B1 (en) 1998-05-05 2002-04-23 Syntex (U.S.A.) Llc Pyrazole derivatives-p38 map kinase inhibitors
IL139169A0 (en) * 1998-05-05 2001-11-25 Hoffmann La Roche Pyrazole derivatives as p-38 map kinase inhibitors
US6316466B1 (en) 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
EP1129091B1 (en) 1998-11-12 2002-10-02 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
ATE240958T1 (de) 1998-11-12 2003-06-15 Neurocrine Biosciences Inc Crf rezeptor-antagonisten und darauf bezogene methoden
FR2789387B1 (fr) 1999-02-04 2001-09-14 Aventis Cropscience Sa Nouveau procede de preparation d'intermediaires pesticides
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US6409988B1 (en) 1999-07-01 2002-06-25 3-Dimensional Pharmaceuticals, Inc. Radiolabeled 1-aryl pyrazoles, the synthesis thereof and the use thereof as pest GABA receptor ligands
US6506784B1 (en) 1999-07-01 2003-01-14 3-Dimensional Pharmaceuticals, Inc. Use of 1,3-substituted pyrazol-5-yl sulfonates as pesticides
WO2001007413A1 (en) 1999-07-22 2001-02-01 3-Dimensional Pharmaceuticals, Inc. 1-aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides
US6545033B1 (en) 1999-10-06 2003-04-08 3-Dimensional Pharmaceuticals, Inc. Fused 1-(2,6-dichloro-4-trifluoromethylphenyl)-pyrazoles, the synthesis thereof and the use thereof as pesticides
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
WO2001058489A1 (en) * 2000-02-14 2001-08-16 Japan Tobacco Inc. Preventives/remedies for postoperative stress
US6531478B2 (en) * 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US20060223824A1 (en) 2000-11-28 2006-10-05 Wyeth Serotonergic agents
GB0100621D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
ES2174757B1 (es) * 2001-04-06 2003-11-01 Esteve Labor Dr Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
CA2443802C (en) 2001-04-27 2010-04-13 Eisai Co., Ltd. Pyrazolo[1,5-a]pyridines and medicines containing the same
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DE10142665B4 (de) 2001-08-31 2004-05-06 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-one und ihre Derivate
WO2003048160A1 (en) * 2001-12-04 2003-06-12 F. Hoffmann-La Roche Ag Ring fused pyrazole derivatives
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2494574C (en) 2002-10-22 2011-05-17 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
JP4401298B2 (ja) * 2002-12-02 2010-01-20 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒｆアンタゴニストとしてのインダゾール誘導体
EP2172197A1 (en) 2002-12-13 2010-04-07 Warner-Lambert Company LLC Octanoic acid derivative to treat fibromyalgia and other pains
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
DE602004018637D1 (de) 2003-04-09 2009-02-05 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
EP1615930A2 (en) 2003-04-09 2006-01-18 Biogen Idec MA, Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists
WO2005009973A1 (en) 2003-06-26 2005-02-03 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
GB0317127D0 (en) * 2003-07-22 2003-08-27 Astex Technology Ltd Pharmaceutical compounds
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
RU2006133265A (ru) * 2004-02-18 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Гетероциклические модуляторы, селективные в отношении подтипа рецептора гамка
EP2336113A1 (en) * 2004-05-29 2011-06-22 7TM Pharma A/S CRTH2 Receptor Ligands for Medical Use
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
GT200600158A (es) * 2005-04-22 2006-11-28 Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
AU2006239922A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
WO2006116150A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EP2254420A4 (en) 2008-02-20 2012-02-15 Targia Pharmaceuticals CNS PHARMACEUTICALS AND METHOD FOR THEIR USE
ES2396126T3 (es) 2008-04-15 2013-02-19 Eisai R&D Management Co., Ltd. Compuesto de 3-fenilpirazol[5,1-b]tiazol
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
PT2471786E (pt) 2009-08-07 2016-03-04 Hoffmann La Roche Derivado de aminopirazol
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
TW201609093A (zh) 2013-12-27 2016-03-16 Chugai Pharmaceutical Co Ltd Ｆｇｆｒ門控蛋白變異基因及以其爲標的之醫藥
WO2016204261A1 (ja) 2015-06-17 2016-12-22 中外製薬株式会社 アミノピラゾール誘導体
WO2017190086A1 (en) 2016-04-29 2017-11-02 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
CA3036195A1 (en) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
EP3563848A1 (en) * 2018-04-30 2019-11-06 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Serpin inhibitors for the treatment of prion and prion-like diseases
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778443A (en) * 1969-02-13 1973-12-11 Ciba Geigy Ag 4-tetrahydro pyridyl,hydroxy alkyl pyrazoles
FR2460299A1 (fr) * 1979-07-05 1981-01-23 Bellon Labor Sa Roger Nouveaux derives du pyrazole et leur application therapeutique
FR2472564A1 (fr) * 1979-12-31 1981-07-03 Bellon Labor Sa Roger Nouveaux aryl-1 arylsulfonyl-4 1h-pyrazolols-3, et procede pour les preparer
DE3602728A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 51373 Leverkusen Schaedlingsbekaempfungsmittel auf basis von pyrazolderivaten
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds

Also Published As

Publication number Publication date
WO1994013643A1 (en) 1994-06-23
IL107946A0 (en) 1994-04-12
EP0674624A1 (en) 1995-10-04
ES2126661T3 (es) 1999-04-01
PL309356A1 (en) 1995-10-02
FI935674A0 (fi) 1993-12-16
MXPA98005325A (es) 2004-08-24
CZ158595A3 (en) 1996-01-17
NO985494D0 (no) 1998-11-25
DE69323212T2 (de) 1999-05-27
DK0674624T3 (da) 1999-09-13
EP0674624B1 (en) 1999-01-20
AU690527B2 (en) 1998-04-30
KR950704261A (ko) 1995-11-17
RU2142946C1 (ru) 1999-12-20
JP2862374B2 (ja) 1999-03-03
DE69323212D1 (de) 1999-03-04
IL107946A (en) 1998-09-24
KR0170567B1 (ko) 1999-02-18
NO952395D0 (no) 1995-06-16
PL175831B1 (pl) 1999-02-26
FI935674L (fi) 1994-06-18
CA2150483A1 (en) 1994-06-23
GR3029568T3 (en) 1999-06-30
NO952395L (no) 1995-08-16
NO304831B1 (no) 1999-02-22
FI113648B (fi) 2004-05-31
EG20397A (en) 1999-02-28
CN1092768A (zh) 1994-09-28
NZ257770A (en) 1997-02-24
NO985494L (no) 1995-08-16
MY131382A (en) 2007-08-30
NO306111B1 (no) 1999-09-20
HU9303591D0 (en) 1994-04-28
HUT67457A (en) 1995-04-28
US5712303A (en) 1998-01-27
CA2150483C (en) 1999-09-14
AU5454894A (en) 1994-07-04
BR9307659A (pt) 1999-06-29
ATE175961T1 (de) 1999-02-15
CZ284157B6 (cs) 1998-08-12
ZA939404B (en) 1995-06-15
MX9308042A (es) 1994-08-31
JPH07509725A (ja) 1995-10-26
CN1060768C (zh) 2001-01-17

Similar Documents

Publication Publication Date Title
TW238303B (zh)
HU9303616D0 (en) Amino-substituted pyrazoles
GR3035414T3 (en) Novel imidazole derivatives, their preparation and therapeutic applications.
HU9501719D0 (en) Polypeptide and anti-hiv agent prepared therefrom
ZA922541B (en) Heterocyclic amines useful in the therapy of asthma and inflammation of the respiratory tract
IL108288A0 (en) Pyrrolidine derivatives, their preparation and medicaments containing them
TW251283B (zh)
IL107917A0 (en) Triazoloquinazolines, their preparation and their use as medicaments